A dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, Denmark and supporters called on the EU Commission to formulate a European protein strategy triggering protests from farmers.

The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.

The Young European Biotech Network (YEBN) is preparing for a busy semester, with a variety of events and initiatives planned through the end of 2024. From launching a new community platform to hosting key events, YEBN aims to support innovation, facilitate collaboration, and address the evolving needs of the biotech community.

Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.

Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).

The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.

After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel (letetresgene autoleucel).

Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via  extracellular vesicles, the next Big thing in the diagnosis and therapy of cancer and cardiovascular diseases

Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.

The study of G protein-coupled receptor (GPCR) signalling is crucial for ­understanding a wide range of physiological processes. Among the methods used to monitor ­calcium ­signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment ­targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.